Phizzle: Reframing Pharma Manufacturing Through Digitized Workflows to Strengthen Data Integrity and Operational Efficiency

In pharmaceutical manufacturing, where precision and compliance are foundational, the processes that support data movement and equipment operation often remain complex and fragmented. The sector is undergoing rapid transformation driven by advancing technology, rising expectations for real-time, data-driven decision-making, and growing pressure to improve efficiency across operations. At the same time, healthcare costs have surpassed $5 trillion in the United States and are increasing at approximately 8% annually, reinforcing the need for more streamlined and reliable systems that can support both compliance and performance.

According to Ben Davis, CEO of Phizzle, the challenge is not rooted in a lack of innovation within the industry, but in the way systems interact. He explains that pharmaceutical environments frequently rely on multiple instruments produced by different manufacturers, each operating with its own interface, communication protocol, and data format. When these systems are brought together, the process of transferring and validating data often becomes dependent on a mix of manual workflows and disconnected tools.

That complexity introduces a level of risk that can be difficult to manage at scale. Davis notes that data integrity remains one of the most persistent concerns in regulated environments, particularly when information must move across multiple systems before reaching its final destination. In such scenarios, he says that even small inconsistencies can create downstream challenges, especially during audits or compliance reviews.

Research highlights that organizations increasingly recognize data quality as a critical factor in operational performance, noting that high accuracy supports reliable decision-making and reduces the risk of errors in analysis and execution. Estimates suggest that managing poor data quality costs each organization approximately $12.9 million annually. Within pharmaceutical manufacturing, where documentation and traceability are essential, this challenge carries additional weight, as even minor inconsistencies can affect both compliance outcomes and operational confidence.

Davis explains how these challenges often originate from the reliance on manual processes that were not designed for today’s level of complexity. “When data is transferred through a combination of handwritten records, manual inputs, and disconnected digital systems, the potential for error increases,” he says. “Over time, these inefficiencies can contribute not only to compliance risks but also to delays in production and product release.”

The operational impact extends beyond documentation. According to Davis, inconsistencies in data handling can lead to lost batches and extended timelines, both of which carry financial and logistical consequences for manufacturers. In an industry where speed to market can influence both patient access and competitive positioning, even incremental delays can become significant.

It is within this context that Davis positions Phizzle as a response to these systemic challenges. He explains that the company’s platform focuses on digitizing manual workflows and standardizing how data is captured, formatted, and transferred across multi-vendor instruments while maintaining the chain of custody, thereby reducing the reliance on disconnected tools and manual intervention. By enabling different instruments to operate through a unified interface and consistent data framework, the platform is designed to address the fragmentation that contributes to data integrity risks.

Davis notes that digitization is increasingly being viewed as a structural shift rather than a technical upgrade. “Standardizing how instruments are operated and how data is captured can reduce variability across systems,” he says. “By enabling different instruments to function within a unified interface and consistent data framework, organizations can simplify workflows that were previously fragmented.”

He further notes that embedding compliance directly into these workflows can help ensure that processes align with regulatory expectations from the outset, rather than relying on retrospective validation. “This approach supports both operational consistency and audit readiness, two priorities that continue to shape how pharmaceutical companies evaluate their systems,” he explains. From his perspective, integrating compliance into digitized workflows is a critical step toward reducing regulatory risk while maintaining operational efficiency.

Technology also plays a role in addressing infrastructure challenges. Davis points to solutions that sit between instruments and networks, allowing data to be securely transferred without requiring direct network connectivity from every device. From his perspective, this architecture can support both security and scalability, particularly in environments where legacy systems remain in use. He notes that approaches like these can help organizations modernize without fully replacing existing infrastructure, which is often a practical consideration in pharmaceutical environments.

At a broader level, Davis suggests that the industry is reaching a point where maintaining traditional workflows may no longer align with current demands. He believes that digitizing these processes is not limited to improving efficiency but also contributes to producing safer and more consistent outcomes. “There is a growing recognition that digitizing manual workflows is necessary because it helps reduce errors, supports compliance, and ultimately contributes to better products reaching the market,” he explains.

Looking ahead, he frames digitization as an ongoing process rather than a single transition. With a developing pipeline of products and continued focus on solving operational challenges, his approach remains centered on addressing the needs of pharmaceutical manufacturers as they evolve.

As regulatory expectations and production demands continue to rise, the conversation around workflow digitization is likely to expand. Davis says, “Organizations that begin investing in more integrated and reliable systems today may be better positioned to navigate the complexities of tomorrow’s pharmaceutical landscape.”